The Potential of Phage Therapy in Sepsis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Jan 10

PMID 29312312

Citations 21

Authors

Andrzej Gorski

Ewa Jonczyk-Matysiak

Marzanna Lusiak-Szelachowska

Ryszard Miedzybrodzki

Beata Weber-Dabrowska

Jan Borysowski

Affiliations

Soon will be listed here.

Abstract

Sepsis remains a difficult clinical challenge, since our understanding of its immunopathology is incomplete and no efficacious treatment currently exists. Its earlier stage results from an uncontrolled inflammatory response to bacteria while in the later stage disturbed immune response with immunodeficiency syndrome develops. More than a hundred of clinical trials have not provided an efficient therapy which could ascertain an improvement or cure. Recent advancements in immunobiology of bacterial viruses (phages) indicate that in addition to their well-known antibacterial action phages have potent immunomodulating properties. Those data along with preliminary observations in experimental animals and the clinic strongly suggest that clinical trials on the efficacy of phages in sepsis are urgently needed.

Citing Articles

Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections.

Guo Z, Yuan M, Chai J Heliyon. 2024; 10(14):e34849.

PMID: 39148970 PMC: 11324966. DOI: 10.1016/j.heliyon.2024.e34849.

Inflammaging in Multidrug-Resistant Sepsis of Geriatric ICU Patients and Healthcare Challenges.

Kumar N, Balraj T, Shivashankar K, Jayaram T, Prashant A Geriatrics (Basel). 2024; 9(2).

PMID: 38667512 PMC: 11049875. DOI: 10.3390/geriatrics9020045.

Multidrug-Resistant Sepsis: A Critical Healthcare Challenge.

Kumar N, Balraj T, Kempegowda S, Prashant A Antibiotics (Basel). 2024; 13(1).

PMID: 38247605 PMC: 10812490. DOI: 10.3390/antibiotics13010046.

Recent Progress in Phage Therapy to Modulate Multidrug-Resistant , including in Human and Poultry.

Zhang Y, Lin Y, Galgano S, Houdijk J, Xie W, Jin Y Antibiotics (Basel). 2022; 11(10).

PMID: 36290064 PMC: 9598230. DOI: 10.3390/antibiotics11101406.

Critical roles of sepsis-reshaped fecal virota in attenuating sepsis severity.

Chancharoenthana W, Sutnu N, Visitchanakun P, Sawaswong V, Chitcharoen S, Payungporn S Front Immunol. 2022; 13:940935.

PMID: 35983067 PMC: 9380439. DOI: 10.3389/fimmu.2022.940935.

References

Diez-Martinez R, de Paz H, Garcia-Fernandez E, Bustamante N, Euler C, Fischetti V . A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. J Antimicrob Chemother. 2015; 70(6):1763-73. DOI: 10.1093/jac/dkv038. View

Takemura-Uchiyama I, Uchiyama J, Osanai M, Morimoto N, Asagiri T, Ujihara T . Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice. Microbes Infect. 2014; 16(6):512-7. DOI: 10.1016/j.micinf.2014.02.011. View

Hattori Y, Hattori K, Suzuki T, Matsuda N . Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction: Novel therapeutic implications and challenges. Pharmacol Ther. 2017; 177:56-66. DOI: 10.1016/j.pharmthera.2017.02.040. View

Lewkowicz N, Mycko M, Przygodzka P, Cwiklinska H, Cichalewska M, Matysiak M . Induction of human IL-10-producing neutrophils by LPS-stimulated Treg cells and IL-10. Mucosal Immunol. 2015; 9(2):364-78. DOI: 10.1038/mi.2015.66. View

Hotchkiss R, Karl I . The pathophysiology and treatment of sepsis. N Engl J Med. 2003; 348(2):138-50. DOI: 10.1056/NEJMra021333. View

Kaufmann S, Dorhoi A, Hotchkiss R, Bartenschlager R . Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2017; 17(1):35-56. PMC: 7097079. DOI: 10.1038/nrd.2017.162. View

Barrow P, Lovell M, Berchieri Jr A . Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol. 1998; 5(3):294-8. PMC: 104512. DOI: 10.1128/CDLI.5.3.294-298.1998. View

Shakoory B, Carcillo J, Chatham W, Amdur R, Zhao H, Dinarello C . Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2015; 44(2):275-81. PMC: 5378312. DOI: 10.1097/CCM.0000000000001402. View

Weber-Dabrowska B, MULCZYK M, Gorski A . Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant Proc. 2003; 35(4):1385-6. DOI: 10.1016/s0041-1345(03)00525-6. View

10.

Buchwald U, Geerdes-Fenge H, Vockler J, Ziege S, Lode H . Interleukin-10: effects on phagocytosis and adhesion molecule expression of granulocytes and monocytes in a comparison with prednisolone. Eur J Med Res. 1999; 4(3):85-94. View

11.

Ali R, Wuescher L, Worth R . Platelets: essential components of the immune system. Curr Trends Immunol. 2016; 16:65-78. PMC: 5096834. View

12.

Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P . Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother. 2012; 56(7):3568-75. PMC: 3393425. DOI: 10.1128/AAC.06330-11. View

13.

Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X . Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. Int J Mol Med. 2006; 17(2):347-55. View

14.

Gu J, Xu W, Lei L, Huang J, Feng X, Sun C . LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol. 2010; 49(1):111-7. PMC: 3020447. DOI: 10.1128/JCM.01144-10. View

15.

Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P . Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother. 2003; 52(6):967-73. DOI: 10.1093/jac/dkg485. View

16.

Laichalk L, Danforth J, Standiford T . Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol. 1996; 15(4):181-7. DOI: 10.1111/j.1574-695X.1996.tb00084.x. View

17.

Lingnau M, Hoflich C, Volk H, Sabat R, Docke W . Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Hum Immunol. 2007; 68(9):730-8. DOI: 10.1016/j.humimm.2007.06.004. View

18.

Graham S, Liles W . Platelets in sepsis: beyond hemostasis. Blood. 2016; 127(24):2947-9. DOI: 10.1182/blood-2016-03-706168. View

19.

Leech J, Lacey K, Mulcahy M, Medina E, McLoughlin R . IL-10 Plays Opposing Roles during Systemic and Localized Infections. J Immunol. 2017; 198(6):2352-2365. PMC: 5337812. DOI: 10.4049/jimmunol.1601018. View

20.

Gilmer D, Schmitz J, Euler C, Fischetti V . Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013; 57(6):2743-50. PMC: 3716137. DOI: 10.1128/AAC.02526-12. View